News

Three Workers Leave Biogen Meeting Testing Positive for Coronavirus

6 March 2020

Three people who have attended a Biogen management meeting in Boston have tested positive for COVID-19 coronavirus. The meeting hosted around 175 co-workers over two days in a Boston hotel.  Before Biogen disclosed these infections, there were only three cases of Coronavirus in Massachusetts. Several other attendees from the meeting reported having flu-like symptoms afterward […]

5 March 2020

CRUK Funds Development of POC Blood-Based Brain Cancer Test

Cancer Research UK (CRUK) has funded a project run by a team of researchers at the University of Bristol to develop a new blood-based test for early diagnosis of brain cancer. The researchers are planning to deploy the point-of-care (POC) assay based on a fluorescent nanophotonics platform, which is a platform that studies the behaviour […]

25 February 2020

New Diagnostic for Coronavirus Receives CE mark

Yesterday, a test developed by Co-diagnostics for the detection of SARS-CoV-2, received CE marking as the virus nears “pandemic” status. CE-IVD marking indicates that the IVD conforms with relevant EU directives regarding the health and safety of the product.

24 February 2020

Alzheimer’s Disease Genetic Research Consortium Launched in New York

York Governor, Andrew Cuomo, announced legislation to launch a consortium of public and private research groups to investigate the genetics of Alzheimer’s disease. The five-year initiative, called the SUNY Curing Alzheimer’s Health Consortium, will analyse the genetics of 1 million people who suffer from or are at risk of developing Alzheimer’s disease over 5 years.

21 February 2020

First High-Quality Eurasian Otter Genome Published

Researchers from the Wellcome Sanger Institute have just released the first high-quality Eurasian Otter (Lutra lutra) genome in partnership with the Cardiff University Otter project, aiming to support the study of their biology and support conservation efforts.

21 February 2020

FDA Releases List of Evidence-Based Pharmacogenetic Variants

Pharmacogenetics (PGx) is the study of how an individual’s genetic makeup affects their drug response and metabolism. An understanding of PGx could help clinicians make prescribing decisions and has the potential to be implemented in routine care worldwide. PGx has understandably been gaining traction and support, with pharmacogenomic elements being implemented into many international Genomic studies.